% | $
Quotes you view appear here for quick access.

Валгрин Ко. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • cmxgen cmxgen Oct 25, 2011 6:14 PM Flag

    95% Estimate

    I thought it was 97%...ESRX also states 0 to 2% rx growth next year.

    esrx will do fine. lets see what cvs says or suggests rx volume will move up.

    This might be hard to stomach if you are a WAG shareholder.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't see ESRX comments as newsworthy to sophisticated shareholders of either company. As you well know, WAG takes a big hit on the front end and ESRX deteriorates gradually for 2 years. The net effect is good for CVS and bad for WAG and ESRX. If ESRX/MHS merger goes through, ESRX may be facing several weak quarters. It's funny also that WAG, while attempting to move Part D business away from ESRX, is strongly promoting it's partnership with Coventry MPD which is a Medco product. Certainly a potential backfire there. The fact that they continue to push Coventry is part of the reason I think WAG plans to ink a contract. Either that or they think the merger won't happen. Time will tell.

76.05-0.74(-0.96%)Dec 30 4:01 PMEST